Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We reiterate our Outperform recommendation on the shares of Aetna Inc. ( AET - Analyst Report ) , prior to the release of its first-quarter earnings scheduled on April 25, 2012, on the basis of its better-than-average operating fundamentals and expected strong performance in 2012.
The company recorded an impressive performance in 2011, with an increase in membership, revenues, operating margins and cash flow on the back of low medical utilization, pricing discipline, medical cost management strategies and cost control initiatives. Aetna also made significant strategic investments in acquisitions and technologies, with the intent to extend its core health business and to capitalize on exciting new consumer and provider opportunities in the marketplace.
Aetna has done well in its Medicare business. The lifting of the Center for Medicare and Medicaid Services (“CMS”) sanctions in June and the acquisition of Genworth's Medicare Supplement business has advanced its Medicare platform. Aetna is focused on developing solutions that help retirees manage their health and employers manage their expenses.
Aetna is looking to generate incremental fee revenues by managing the infrastructure necessary for care organizations.
With respect to Aetna’s international business, the product launches in China, earlier during the year, met with initial success The company also entered the Indian market with the acquisition of Indian Health Organization. These are indicative of Aetna’s efforts to expand its global footprint and develop new business models.
Aetna has made a number of acquisitions in its Commercial business such as Prodigy. Prodigy's highly-customized offering addresses a portion of the self-funded market, covering approximately 27 million lives. Additionally the company also acquired PayFlex, an administrator of Flexible Spending Accounts (FSAs), Health Savings Accounts (HSAs) and other accounts that support consumer-based health plan designs.
Aetna’s balance sheet is quite strong with a moderate leverage. Its excess cash generation in 2011 enabled it to complete 4 significant acquisitions, repurchase 45 million shares and institute a meaningful shareholder dividend.
However, some uncertainties regarding the final outcome of the Health Care Reform, higher expected utilization in 2012 and a low interest rate environment are some of the headwinds faced by the company.
Aetna currently retains a Zacks #1 Rank, which translates into a short-term Buy rating. The health insurer competes with other carriers such as UnitedHealth Group Inc. ( UNH - Analyst Report ) , CIGNA Corp. ( CI - Analyst Report ) , WellPoint Inc. ( WLP - Analyst Report ) and Humana Inc. ( HUM - Analyst Report ) .
Read the full Analyst Report on AET
Read the full Analyst Report on WLP
Read the full Analyst Report on HUM
Read the full Analyst Report on CI
Read the full Analyst Report on UNH